Do analysts prefer AKTX or BYSI?

Akari Therapeutics presently has a consensus price target of $89.00, indicating a potential upside of 713.53%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Akari Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, AKTX or BYSI?

BeyondSpring has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A BeyondSpring $1.75M 37.83 -$1.01M -$0.14 N/A

Is AKTX or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% BeyondSpring N/A N/A -14.00%

Which has preferable valuation and earnings, FLNA or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is FLNA or AKTX more profitable?

Cassava Sciences' return on equity of -53.90% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Akari Therapeutics N/A -123.29% -63.01%

Which has higher earnings and valuation, CLNN or AKTX?

Akari Therapeutics has lower revenue, but higher earnings than Clene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 384.04 -$26.17M -$3.20 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is CLNN or AKTX more profitable?

Akari Therapeutics has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Akari Therapeutics N/A -123.29% -63.01%

Which has better valuation and earnings, UPXI or AKTX?

Upexi has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $26.14M 2.44 -$13.68M -$0.62 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is UPXI or AKTX more profitable?

Akari Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Akari Therapeutics N/A -123.29% -63.01%

Does the media prefer UPXI or AKTX?

In the previous week, Upexi had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Upexi and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.75 beat Upexi's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AKTX or TCRX?

Akari Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A TScan Therapeutics $9.14M 6.58 -$129.77M -$0.96 N/A

Akari Therapeutics (AKTX) Competitors

$10.94 -1.06 (-8.83%)

Closing price 04:00 PM Eastern

Extended Trading

$10.92 -0.02 (-0.18%)

As of 04:50 PM Eastern

Compare

AKTX vs. BYSI, FLNA, CLNN, UPXI, and TCRX

Should you buy Akari Therapeutics stock or one of its competitors? MarketBeat compares Akari Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akari Therapeutics include BeyondSpring (BYSI), Cassava Sciences (FLNA), Clene (CLNN), Upexi (UPXI), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.

How does Akari Therapeutics compare to BeyondSpring?

Akari Therapeutics (NASDAQ:AKTX) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Akari Therapeutics presently has a consensus price target of $89.00, indicating a potential upside of 713.53%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Akari Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Akari Therapeutics had 1 more articles in the media than BeyondSpring. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for BeyondSpring. Akari Therapeutics' average media sentiment score of 0.75 beat BeyondSpring's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akari Therapeutics	Positive
BeyondSpring	Neutral

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Akari Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

BeyondSpring has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
BeyondSpring	$1.75M	37.83	-$1.01M	-$0.14	N/A

BeyondSpring's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
BeyondSpring	N/A	N/A	-14.00%

Summary

Akari Therapeutics beats BeyondSpring on 7 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Akari Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Cassava Sciences. Akari Therapeutics' average media sentiment score of 0.75 beat Cassava Sciences' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Neutral
Akari Therapeutics	Positive

Cassava Sciences presently has a consensus price target of $5.00, suggesting a potential upside of 309.84%. Akari Therapeutics has a consensus price target of $89.00, suggesting a potential upside of 713.53%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Cassava Sciences' return on equity of -53.90% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Akari Therapeutics	N/A	-123.29%	-63.01%

Summary

Akari Therapeutics beats Cassava Sciences on 8 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Clene?

Clene (NASDAQ:CLNN) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Akari Therapeutics has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Akari Therapeutics	N/A	-123.29%	-63.01%

In the previous week, Akari Therapeutics had 1 more articles in the media than Clene. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Clene. Akari Therapeutics' average media sentiment score of 0.75 beat Clene's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Clene	Neutral
Akari Therapeutics	Positive

Clene presently has a consensus price target of $33.25, suggesting a potential upside of 453.24%. Akari Therapeutics has a consensus price target of $89.00, suggesting a potential upside of 713.53%. Given Akari Therapeutics' higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Akari Therapeutics has lower revenue, but higher earnings than Clene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	384.04	-$26.17M	-$3.20	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Clene has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

23.3% of Clene shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Akari Therapeutics beats Clene on 8 of the 13 factors compared between the two stocks.

How does Akari Therapeutics compare to Upexi?

Upexi (NASDAQ:UPXI) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Upexi has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Akari Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Akari Therapeutics	N/A	-123.29%	-63.01%

In the previous week, Upexi had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Upexi and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.75 beat Upexi's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akari Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.7% of Upexi shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 9.0% of Upexi shares are held by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Upexi has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$26.14M	2.44	-$13.68M	-$0.62	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Upexi currently has a consensus target price of $8.33, suggesting a potential upside of 818.17%. Akari Therapeutics has a consensus target price of $89.00, suggesting a potential upside of 713.53%. Given Upexi's stronger consensus rating and higher possible upside, equities analysts plainly believe Upexi is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Upexi beats Akari Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Akari Therapeutics compare to TScan Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Akari Therapeutics has higher earnings, but lower revenue than TScan Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
TScan Therapeutics	$9.14M	6.58	-$129.77M	-$0.96	N/A

Akari Therapeutics presently has a consensus target price of $89.00, suggesting a potential upside of 713.53%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 552.17%. Given Akari Therapeutics' higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Akari Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for TScan Therapeutics. Akari Therapeutics' average media sentiment score of 0.75 beat TScan Therapeutics' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akari Therapeutics	Positive
TScan Therapeutics	Neutral

Akari Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Akari Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Summary

Akari Therapeutics beats TScan Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTX vs. The Competition

Export

Metric	Akari Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.47M	$3.39B	$6.41B	$12.60B
Dividend Yield	N/A	2.27%	2.67%	5.69%
P/E Ratio	N/A	19.40	24.46	24.45
Price / Sales	N/A	325.98	554.57	123.58
Price / Cash	N/A	125.35	43.94	55.48
Price / Book	0.44	8.18	10.71	6.59
Net Income	-$17.30M	$23.89M	$3.57B	$337.29M
7 Day Performance	-26.18%	2.74%	0.66%	0.59%
1 Month Performance	215.36%	5.16%	3.66%	4.47%
1 Year Performance	-76.22%	53.63%	28.47%	31.21%

Akari Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTX Akari Therapeutics	2.9527 of 5 stars	$10.94 -8.8%	$89.00 +713.5%	-74.6%	$12.47M	N/A	N/A	9
BYSI BeyondSpring	0.0475 of 5 stars	$1.72 +1.2%	N/A	-53.2%	$69.90M	$1.75M	N/A	80	Gap Down
FLNA Cassava Sciences	1.3702 of 5 stars	$1.42 -0.7%	$5.00 +252.1%	-41.5%	$69.08M	N/A	N/A	20
CLNN Clene	3.0444 of 5 stars	$5.57 +4.5%	$33.25 +496.9%	+40.2%	$68.11M	$200K	N/A	100
UPXI Upexi	2.1489 of 5 stars	$0.89 -6.2%	$8.33 +835.3%	-90.3%	$66.76M	$15.81M	N/A	130	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akari Therapeutics (AKTX) Competitors

AKTX vs. BYSI, FLNA, CLNN, UPXI, and TCRX

How does Akari Therapeutics compare to BeyondSpring?

Summary

How does Akari Therapeutics compare to Cassava Sciences?

Summary

How does Akari Therapeutics compare to Clene?

Summary

How does Akari Therapeutics compare to Upexi?

Summary

How does Akari Therapeutics compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akari Therapeutics (AKTX) Competitors

AKTX vs. BYSI, FLNA, CLNN, UPXI, and TCRX

How does Akari Therapeutics compare to BeyondSpring?

Do analysts prefer AKTX or BYSI?

Does the media refer more to AKTX or BYSI?

Do insiders & institutionals believe in AKTX or BYSI?

Which has more volatility & risk, AKTX or BYSI?

Which has preferable valuation and earnings, AKTX or BYSI?

Is AKTX or BYSI more profitable?

Summary

How does Akari Therapeutics compare to Cassava Sciences?

Does the media prefer FLNA or AKTX?

Do analysts prefer FLNA or AKTX?

Do insiders & institutionals hold more shares of FLNA or AKTX?

Which has preferable valuation and earnings, FLNA or AKTX?

Which has more volatility & risk, FLNA or AKTX?

Is FLNA or AKTX more profitable?

Summary

How does Akari Therapeutics compare to Clene?

Is CLNN or AKTX more profitable?

Does the media prefer CLNN or AKTX?

Do analysts recommend CLNN or AKTX?

Which has higher earnings and valuation, CLNN or AKTX?

Which has more volatility & risk, CLNN or AKTX?

Do institutionals & insiders hold more shares of CLNN or AKTX?

Summary

How does Akari Therapeutics compare to Upexi?

Which has more volatility and risk, UPXI or AKTX?

Is UPXI or AKTX more profitable?

Does the media prefer UPXI or AKTX?

Do institutionals & insiders have more ownership in UPXI or AKTX?

Which has better valuation and earnings, UPXI or AKTX?

Do analysts rate UPXI or AKTX?

Summary

How does Akari Therapeutics compare to TScan Therapeutics?

Which has stronger earnings and valuation, AKTX or TCRX?

Do analysts recommend AKTX or TCRX?

Do insiders & institutionals hold more shares of AKTX or TCRX?

Does the media prefer AKTX or TCRX?

Is AKTX or TCRX more profitable?

Which has more volatility and risk, AKTX or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools